BioSpace8d
J&J’s Spravato Makes Headway in Tough Depression Space With Monotherapy Approval
Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...
FDA approves J&J’s nasal spray for severe depression as stand-alone treatment
Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...
FDA approves Johnson & Johnson's nasal spray for depression as standalone treatment
The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major ...
NBC New York9d
FDA approves Johnson & Johnson's nasal spray for depression as standalone treatment
Mattingly said patients can now choose to take Spravato with or without an oral antidepressant, especially if those pills aren't improving their symptoms and are causing undesirable side effects ...